Form 4: ANI Pharmaceuticals Executive Christopher Mutz Sells 2,000 Shares
SEC Form 4 Filing
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 2,000 shares of common stock at a price of $61.61 on May 21, 2024.
Summary
- On May 21, 2024, Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 2,000 shares of the company's common stock.
- The transaction was executed at a price of $61.61 per share.
- Following the transaction, Mutz directly owns 83,277 shares of ANI Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares by an executive.
Industry Context
Executive stock sales are a common occurrence and can be for various personal financial reasons. It's important to consider the overall trend of insider transactions and the company's performance when interpreting such sales.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact unless part of a larger trend.
Key Dates
| Date | Description |
|---|---|
| 05/21/2024 | Date of transaction: Christopher Mutz sold 2,000 shares of ANI Pharmaceuticals common stock. |
| 05/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.